A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
University of Colorado, Denver
GlaxoSmithKline
University of Nebraska
Novartis